What question did this study set out to answer?

To determine whether recombinant human erythropoietin (rhEPO) improves functional neurological recovery and mitigates secondary tissue injury when administered after traumatic spinal cord trauma.

June 24, 2002Proceedings of the National Academy of Sciences

Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma

View Full Paper

Ask AI

Bookmark

To determine whether recombinant human erythropoietin (rhEPO) improves functional neurological recovery and mitigates secondary tissue injury when administered after traumatic spinal cord trauma.
Evaluated two rodent models of spinal injury: a moderate T3 compression injury (0.6 N clip for 1 min) and a severe T9 contusion injury (1 N).
Administered systemic rhEPO intraperitoneally (1,000 units/kg immediately post-compression or 5,000 units/kg at 1 hour post-contusion) compared against vehicle saline controls.
In the compression model, rhEPO initiated partial motor recovery within 12 hours post-injury and achieved nearly complete functional recovery by day 28, whereas saline-treated controls displayed only poor recovery.
In the severe contusion model, rhEPO produced superior motor recovery over controls, significantly attenuated secondary inflammation, and reduced spinal tissue cavitation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Experimental study demonstrates enhanced neurological recovery following erythropoietin treatment in rodent spinal cord injury, indicating strong neuroprotective and antiinflammatory potential.

Cite This Study

Gorio et al. (2002) studied this question.

synapsesocial.com/papers/6a09eedf4b13cba792517ed0 https://doi.org/10.1073/pnas.142287899

View Full Paper

Ask AI

Bookmark

Implication

Experimental study demonstrates enhanced neurological recovery following erythropoietin treatment in rodent spinal cord injury, indicating strong neuroprotective and antiinflammatory potential.

Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma

Key Points

Discussion

Implication

Cite This Study

Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider